secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001628280-26-001335
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira reports preliminary 2025 revenue of $726.4M; EXPAREL sales record high with 7% volume growth
--------------------------------------------------------------------------------

- Total revenue $726.4M vs $701.0M in FY2024, up 3.6%.
- Q4 EXPAREL net sales $155.8M (record) vs $147.7M in Q4 2024, 7% volume growth.
- Full-year EXPAREL net sales $575.1M vs $549.0M (+4.8%); ZILRETTA flat at $116.6M.
- Repurchased 2.0M shares for $50.0M in Q4; $150M remains under current authorization.
- Preliminary unaudited; full Q4/fiscal 2025 results and guidance expected later in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/0001628280-26-001335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/pcrx-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer